Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate

Eur Heart J Suppl. 2019 Feb;21(Suppl A):A28-A33. doi: 10.1093/eurheartj/suy035. Epub 2019 Feb 26.


Hyperkalaemia is a life-threatening condition, resulting from decreased renal function or dysfunctional homoeostatic mechanisms, often affecting patients with cardiovascular (CV) disease. Drugs such as renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in CV patients but can also cause drug-induced hyperkalaemia. New therapeutic options exist to enhance potassium excretion in these patients. To this aim, we reviewed pharmacological properties and available data on patiromer and sodium zirconium cyclosilicate for the treatment of hyperkalaemia. These agents have been shown in randomized trials to significantly reduce serum potassium in patients with hyperkalaemia on renin-angiotensin-aldosterone system inhibitors. Additional research should focus on their long-term effects/safety profiles and drug-drug interactions.

Keywords: Cardiovascular patients; Hyperkalaemia; Patiromer; Sodium zirconium cyclosilicate.